NCT02638116View on ClinicalTrials.gov

A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Healthy

Interventions

DRUG

Ibrutinib

Ibrutinib will be administered at a dose of 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7.

DRUG

Omeprazole

Omeprazole will be administered at dose of 40 mg tablets orally once daily from Day 3 to Day 7.

Trial Locations (1)

Unknown

Antwerp

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02638116 - A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults | Biotech Hunter | Biotech Hunter